Note 10 - Share-based Compensation - Schedule of Allocated Expense (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Mar. 31, 2025 |
Mar. 31, 2024 |
Mar. 31, 2025 |
Mar. 31, 2024 |
|
Share-based compensation expense | $ 2,223,843 | $ 3,634,171 | $ 4,897,948 | $ 7,041,120 |
FC2 Female Condom [Member] | Discontinued Operations, Disposed of by Sale [Member] | ||||
Share-based compensation expense, discontinued operations | 0 | 504,420 | (10,049) | 1,027,566 |
Selling, General and Administrative Expenses [Member] | ||||
Share-based compensation expense | 1,618,958 | 2,294,427 | 3,623,674 | 4,694,851 |
Research and Development Expense [Member] | ||||
Share-based compensation expense | $ 604,885 | $ 835,324 | $ 1,284,323 | $ 1,318,703 |
X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of expense (benefit) for award under share-based payment arrangement. Excludes amount capitalized. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|